Serum-based analysis included 11 candidate miRNAs with significant expression differences in the renal tissue between AAV-GN and non-AAV RD, MPO- and PR3-positive AAV-GN, and/or AAV-GN and bystander ANCA samples (validated miRNAs). The gene discussed is MPO; the disease is ganglioneuroma.